Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Suzhou City, China Clinical Trials

A listing of Suzhou City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (85) clinical trials

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer

Phase

0.05 miles

Learn More »

Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT

Allo-HSCT is the most effective treatment stratagey for high risk acute myeloid leukemia. At present, modified BUCY is the standard conditioning regimen for AML undergoing allo-HSCT in our institute. However, relapse occured in as high as 30-50% high risk AML patients after allo-HSCT. Thus, the best conditioning regimen for this ...

Phase

0.05 miles

Learn More »

Enhanced Recovery After Surgery Program for Colorectal Cancer: a Multi-center Study (ERASC1)

In China, Europe and America, colorectal cancer is one of common malignant tumors. It is very important for treatment of colorectal cancer to enhance the quality of treatment, increase patients' survival rate and improve the life quality. So far, surgical resection is optimal treatment for patients with colorectal cancer. As ...

Phase N/A

0.05 miles

Learn More »

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

This is an open-label, single-centre, randomised study, looking at a series of 40 patients up to the age of 75 with newly diagnosed Waldenstrom's macroglobulinemia (WM) not previously treated. Patients will receive RCD or PCD combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try ...

Phase

0.05 miles

Learn More »

Individualized Precise Radiotherapy With the Guidance of Radiosensitivity of Locally Advanced Cervical Cancer

Cisplatin-based chemoradiation (CCRT) has been considered as the standard care for patients with locally advanced cervical cancer (LACC). Nevertheless, increasingly more radio-resistant tumors still recur. IMRT including Rapid-Arc have obvious advantage in the dose distribution and organ protection, and positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) and Comet analysis ...

Phase

0.05 miles

Learn More »

Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

Design: The study is a multi-center, randomized,controlled non-inferiority trial. Population: patients with newly diagnosed drug-susceptible pulmonary TB who fulfill the inclusion and exclusion criteria. Investigational regimens: Experimental group 1 regimen consists of levofloxacin, isoniazid , rifampicin,ethambutol and pyrazinamide for 4.5 months. Experimental group 2 regimen consists of isoniazid, rifampicin, ethambutol ...

Phase

0.05 miles

Learn More »

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

Adults ages 18-75 with high risk Multiple Myelomas (not achieved VGPR before stem cell mobilization or R-ISS III stage or with extramedullary infiltration or with del(17p), t(4;14), t(14;16)). Design Participants may be screened with:Medical historyPhysical examBlood and urine testsHeart testsBone marrow sampleMultiple scans and X-rays. Participants will have apheresis. Blood ...

Phase

0.05 miles

Learn More »

Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer

This is a double-blind, placebo controlled, randomized multicenter global phase 3 study comparing the efficacy and safety of single agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo as maintenance therapy in subjects with advanced gastric cancer who have responded to first line platinum based chemotherapy. Subjects are randomized 1:1 ...

Phase

0.05 miles

Learn More »

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

Phase

0.05 miles

Learn More »

A Study of MEDI4736 With Tremelimumab MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma

This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 (Durvalumab) in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in subjects with unresectable hepatocellular carcinoma.

Phase

0.27 miles

Learn More »